Reviewing the inter partes review

The establishment of the US Patent Trial and Appeal Board (PTAB) in 2012 changed the game for patent owners. And while life science patents have not always been under the spotlight, recent trends suggest more such patents are being reviewed than ever before.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Emotional Perception exclusive: ‘We are now very much open for business’

16 February 2026 Following the UK Supreme Court’s recent landmark judgment, which ushers in a sea-change to patent law, the team behind a groundbreaking AI-related invention sit down with Sarah Speight to explain how they got here, and why the ruling changes everything.

Careers

Norton Rose Fulbright expands pharma and biotech disputes team

13 February 2026 The firm recruits two Cooley partners with expertise in Hatch-Waxman, BPCIA, trade secrets, and competitor versus competitor patent litigation.

Europe

UPC appeals court confirms ‘all-or-nothing’ rule for unitary patents

12 February 2026 The court has denied a German non-practising entity’s bid to secure unitary protection for a patent that it has asserted against Intel.

More features

Emotional Perception exclusive: ‘We are now very much open for business’

New rankings recognise top US patent firms and lawyers

Norton Rose Fulbright expands pharma and biotech disputes team

UPC appeals court confirms ‘all-or-nothing’ rule for unitary patents

Honigman bags second Kirkland litigator this year for IP team

Reaction: Emotional Perception decision is ‘good for UK PLC’

UK ruling ‘future-proofs’ patentability for AI and computer tech

The curtain closes on three major drug disputes

Reviewing the inter partes review

More on this story

Editor's picks

Editor's picks

More features